Well Referenced

Tag: ulcerative colitis

First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses

This 2014 multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of LT-02, a modified-release phosphatidylcholine formulation, in patients with mesalazine-refractory ulcerative colitis. Conducted across 24 centers in Germany, Lithuania, and Romania, 156 patients were assigned to receive placebo or LT-02 at doses of 0.8, 1.6, or 3.2 g/day

Read More »
June 26, 2025 No Comments

Protective effect of methylene blue on TNBS-induced colitis in rats mediated through the modulation of inflammatory and apoptotic signalling pathways

This 2019 study investigated the therapeutic potential of methylene blue (MB) in a rat model of trinitrobenzene sulfonic acid (TNBS)-induced colitis, simulating ulcerative colitis. MB was administered intraperitoneally at doses of 1, 2, and 4 mg/kg, compared to a control group receiving sulfasalazine (500 mg/kg orally). MB treatment resulted in

Read More »
June 26, 2025 No Comments

Emerging treatments for ulcerative colitis: a systematic review

This 2017 systematic review analyzed 21 studies involving 11,524 adults to evaluate novel therapeutic options for ulcerative colitis (UC). Thirteen new treatments were identified. Vedolizumab and golimumab demonstrated superiority over placebo for both induction and maintenance therapy. Tofacitinib showed dose-dependent efficacy for induction therapy. Etrolizumab achieved higher clinical remission rates

Read More »
June 26, 2025 No Comments

Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977–2014

This 2019 Danish nationwide cohort study examined the long-term risk of Parkinson’s disease (PD) among individuals with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. Using national registry data from 1977 to 2014, the study followed 76,477 IBD patients and over 7.5 million controls. Results showed a significantly

Read More »
June 26, 2025 No Comments

Utility of faecal calprotectin analysis in adult inflammatory bowel disease

This study explores the use of faecal calprotectin (FC) measurement as a non-invasive biomarker for diagnosing and managing inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Elevated FC levels correlate with active disease and can help distinguish IBD from other gastrointestinal conditions like irritable bowel syndrome

Read More »
June 26, 2025 No Comments

Calprotectin in inflammatory bowel disease

This review article explores the role of calprotectin as a key biomarker in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Elevated levels of calprotectin are closely associated with disease activity, making it an effective non-invasive marker for diagnosing IBD, assessing disease severity, monitoring treatment response, and predicting

Read More »
June 26, 2025 No Comments

Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing

This 2017 observational study published in Gastroenterology (PMID: 28601482) examined the role of intestinal permeability in patients with Inflammatory Bowel Disease (IBD) who had achieved mucosal healing but continued to experience bowel symptoms. Among 88 IBD patients (31 with ulcerative colitis and 57 with Crohn’s disease), 16.3% reported ongoing symptoms

Read More »
June 26, 2025 No Comments

Mucosal protection by phosphatidylcholine

This review explores the role of phosphatidylcholine (PC) in maintaining colonic mucosal integrity and its therapeutic potential for ulcerative colitis (UC). PC forms a hydrophobic barrier in the intestines, preventing bacterial invasion and inflammation, but in UC patients, there is a significant reduction in mucus PC content, making them more

Read More »
June 26, 2025 No Comments

Methylene Blue: Revisited

This systematic review evaluates the safety and efficacy of 5-aminosalicylic acid (5-ASA) for treating ulcerative colitis (UC), finding it effective in both inducing and maintaining remission in UC patients. The study showed remission rates of 50-60% depending on the dosage, with minimal side effects such as headaches and gastrointestinal disturbances.

Read More »
June 26, 2025 No Comments